J. Bauman

C. Rudin, J. Nemunaitis, B. Halmos, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The phosphatidyl-inositol 3-kinase/Akt/mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer

J. Bauman, S. Khan, 2014 .

Brain Metastases from Non-Small Cell Lung Cancer: Clinical Benefits of Erlotinib and Gefitinib

J. Bauman, Dennie V. Jones, O. Sanaei, 2014 .

Targeting NEDDylation as a Novel Approach to Improve the Treatment of Head and Neck Cancer

J. Bauman, J. Carew, S. Nawrocki, 2021, Cancers.

Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome

D. Wood, H. Vesselle, J. Bauman, 2019, BMC Cancer.

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.

Simion I. Chiosea, Kelsey P. Pendleton, A. McKenna, 2015, JAMA oncology.

Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations

J. Bauman, K. Eaton, R. Martins, 2007, Clinical Cancer Research.

Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions

Charles S. Coffey, Chiu-Hsieh Hsu, O. Harismendy, 2021, JCI insight.

798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update

J. Bauman, H. Burris, J. Frederick, 2020 .

Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition.

J. Bauman, B. Burtness, T. Galloway, 2013, The Lancet. Oncology.

Comment on “Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling”

R. Mehra, E. Golemis, J. Bauman, 2012, Science Signaling.

IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.

A. Egloff, Lin Wang, J. Grandis, 2017, Oral oncology.

Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.

Simion I. Chiosea, G. Mills, A. Jimeno, 2017, JCI insight.

Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients

J. Grandis, Seungwon Kim, J. Bauman, 2019, Clinical Cancer Research.

Phase 1 study of EGFR‐antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives

D. Heron, J. Grandis, Seungwon Kim, 2018, Cancer.

A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies

S. Belinsky, J. Bauman, C. Muller, 2012, Cancer Chemotherapy and Pharmacology.

Precision medicine: Sustained response to erdafitinib in FGFR2 ‐mutant, multiply recurrent ameloblastoma

J. Bauman, Ghassan A Tranesh, Katherine A. Lawson-Michod, 2022, Cancer reports.

Upregulation of the ATR‐CHEK1 pathway in oral squamous cell carcinomas

J. Bauman, L. Appleman, S. Gollin, 2014, Genes, chromosomes & cancer.

Cancer of the oropharynx.

R. Ferris, J. Bauman, D. Clump, 2015, Surgical oncology clinics of North America.

Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism

J. Bauman, J. Carew, S. Nawrocki, 2022, Cell Death & Disease.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting

B. Fox, B. O'Sullivan, D. Brizel, 2017, Cancer.

Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.

D. Hayes, N. Futran, E. Mendez, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Clinical Algorithm for Fine-Needle Aspiration Molecular Testing Effectively Guides the Appropriate Extent of Initial Thyroidectomy

M. Tublin, M. Nikiforova, Y. Nikiforov, 2014, Annals of surgery.

Promising systemic immunotherapies in head and neck squamous cell carcinoma.

R. Ferris, J. Bauman, N. Gildener-Leapman, 2013, Oral oncology.

Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer

J. Bauman, Y. Rao, J. Goodman, 2023, Cancers.

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Nofisat Ismaila, L. Mell, J. Bauman, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

J. Grandis, A. Argiris, J. Bauman, 2016, Head & neck.

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.

G. Olson, C. Chung, E. Fertig, 2013, Oral oncology.

First-in-human study of AMG 900, an oral pan-Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors.

M. Carducci, J. Bauman, C. Verschraegen, 2012 .

An enhanced role for palliative care in the multidisciplinary approach to high‐risk head and neck cancer

D. Heron, J. Bauman, R. Arnold, 2016, Cancer.

Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer

Simion I. Chiosea, J. Siegfried, Lin Wang, 2014, Clinical Cancer Research.

A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers

S. Belinsky, J. Bauman, C. Verschraegen, 2014, Translational oncology.

Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer

Simion I. Chiosea, G. Mills, S. Vandenberg, 2019, The Journal of experimental medicine.

Current Concepts in Chemotherapy for Head and Neck Cancer.

J. Bauman, S. Sindhu, 2019, Oral and maxillofacial surgery clinics of North America.

A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer.

E. Vokes, T. Seiwert, J. Bauman, 2015 .

Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

Sourav Bandyopadhyay, N. Krogan, J. Grandis, 2018, Cancer research.

Human Papillomavirus-Associated Adenocarcinoma of the Base of Tongue: Potentially Actionable Genetic Changes

Simion I. Chiosea, R. Seethala, M. Nikiforova, 2014, Head and Neck Pathology.

Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.

D. Heron, J. Johnson, R. Ferris, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

When the Damage Is Done: Selecting Patients for Head and Neck Cancer Chemoprevention Trials

J. Bauman, Daniel E. Johnson, 2017, Cancer Prevention Research.

Persistent Salivary Human Papillomavirus DNA as a Surveillance Biomarker: Not Just Spitting in the Wind.

R. Ferris, J. Bauman, 2015, JAMA oncology.

Neoadjuvant chemotherapy improves survival compared with concurrent chemoradiation alone in nasopharyngeal carcinoma patients with N3 disease

J. Bauman, Steven J. Wang, J. Robbins, 2019, Head & neck.

Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.

G. Mills, N. Krogan, J. Grandis, 2021, The Journal of clinical investigation.

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma

Jing Wang, Jill Gilbert, Nabil F. Saba, 2015, Clinical Cancer Research.

Association of pretreatment body mass index and survival in human papillomavirus positive oropharyngeal squamous cell carcinoma.

D. Heron, R. Ferris, Seungwon Kim, 2016, Oral oncology.

Correlation of anti-tumor adaptive immunity with clinical response in a phase II "Window" trial of neoadjuvant cetuximab in patients with resectable stage III-IV head and neck squamous carcinoma (HNSCC).

D. Heron, R. Ferris, Seungwon Kim, 2016 .

Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups

J. Bauman, R. Hromas, C. Wiggins, 2014, Leukemia & lymphoma.

Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients

J. Nieva, S. Ou, P. Bunn, 2013, Cancer.

Author Correction: Head and neck squamous cell carcinoma

C. R. Leemans, J. Grandis, J. Bauman, 2023, Nature Reviews Disease Primers.

CHK It Out! Blocking WEE Kinase Routs TP53 Mutant Cancer

C. Chung, J. Bauman, 2014, Clinical Cancer Research.

Radiology, D. Mankoff, J. Bauman, 2010 .

Phase 2a Study of Cetuximab and Dasatinib in Patients With Cetuximab-Resistant Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

A. Egloff, J. Grandis, J. Bauman, 2016 .

A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab

E. Fertig, V. Badovinac, J. Bauman, 2019, Biomarker Research.

E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC).

C. Chung, A. Cmelak, R. Ferris, 2013 .

Can Pha Iodi Met with

D. Mankoff, J. Bauman, K. Eaton, 2010 .

Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin: NRG-HN004.

Steven S. Chang, Q. Le, A. Minn, 2019, Journal of Clinical Oncology.

Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer

J. Bauman, C. Caulin, B. Burtness, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome

D. Wood, H. Vesselle, J. Bauman, 2019, BMC Cancer.

Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: A phase II randomized trial.

D. Hayes, B. Kurland, J. Liao, 2012 .

ECHO-310: A phase 3, randomized trial of epacadostat + nivolumab + chemo vs EXTREME as first-line treatment of recurrent/metastatic SCCHN.

R. Mehra, J. Bauman, A. Psyrri, 2018 .

Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

D. Mankoff, J. Bauman, K. Eaton, 2010, Clinical Cancer Research.

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma

A. Jimeno, D. Raben, R. Mehra, 2015, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

A phase Ib study of CUDC-101, a multitargeted inhibitor of EGFR, HER2, and HDAC, in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer.

J. Nemunaitis, J. Bauman, G. Dy, 2012 .

ne-Refractory Differentiated Thyroid Cancer and astatic Medullary Carcinoma of the Thyroid

D. Mankoff, J. Bauman, K. Eaton, 2010 .

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

J. Grandis, A. Argiris, J. Bauman, 2016, Head & neck.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Simion I. Chiosea, R. Herbst, Lin Wang, 2016, The Journal of clinical investigation.

C. Rudin, A. Jimeno, J. Bauman, 2015, Oral oncology.

Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition.

J. Bauman, B. Burtness, T. Galloway, 2013, The Lancet. Oncology.

STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer.

J. Grandis, Hua Li, J. Bauman, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Feasibility of 5‐fluorouracil and imiquimod for the topical treatment of cervical intraepithelial neoplasias (CIN) 2/3

J. Bauman, Sopan Mohnot, S. O'Connor, 2023, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance.

Chiu-Hsieh Hsu, H. Parnes, J. Schlom, 2022, Journal of Clinical Oncology.